Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now early-phase tilt

Early Stage Breast Cancer: early-phase trial registry

14 of 22 indexed Early Stage Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #756 of 28,707 conditions by registered trial count.

22 US clinical trials · 14 currently recruiting · #756 of 28,707 conditions by registered trial count

Early Stage Breast Cancer: 22 US clinical trials tracked, 14 recruiting.

Early Stage Breast Cancer is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Dana-Farber Cancer Institute, running 3 of these trials.

Enrollment posture brief

Registry condition early-stage-breast-cancer

OPEN 14 | RECR 64% | LATE 0 | EARLY 11 | RANK #756 | SPON 3

Nearest open-share peer: Autoimmune Disease (64% recruiting · 11 trials)

Early Stage Breast Cance (th…64%Advanced Melanoma63.6%Acute Myeloid Leukemia Arisi18.2%Adenocarcinoma of the Prosta0%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Early Stage Breast Cancer

Early Stage Breast Cancer lists 14 open slots (64% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Early Stage Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Early Stage Breast Cancer is recruiting above its size-band peers.

    14 of 22 indexed trials (63.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Early Stage Breast Cancer trials is spread across many organizations.

    Dana-Farber Cancer Institute accounts for 3 of 22 trials (13.6%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Most Early Stage Breast Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 90 among the 22 trials that report a genuine target (sentinel values excluded). 14 of those (63.6%) plan for fewer than 100 participants.

  4. Early Stage Breast Cancer research is mostly interventional.

    18 interventional and 4 observational studies make up this index (81.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 29

Open and recent trials

22 total, page 1 of 1

RECRUITING Phase 2 5,000 participants

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

QuantumLeap Healthcare Collaborative

NCT01042379

RECRUITING 1,000 participants

Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer

Saint John's Cancer Institute

NCT04603209

RECRUITING 900 participants

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Tempus AI

NCT07211178

RECRUITING NA 450 participants

Cardiometabolic Screening Program

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT05386719

RECRUITING NA 152 participants

Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT04458532

RECRUITING Phase 2 90 participants

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

UNC Lineberger Comprehensive Cancer Center

NCT06902311

RECRUITING Phase 2 88 participants

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Jonsson Comprehensive Cancer Center

NCT04553770

RECRUITING Phase 2 62 participants

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

Dartmouth-Hitchcock Medical Center

NCT07071038

RECRUITING Phase 2 60 participants

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Rutgers, The State University of New Jersey

NCT05559164

RECRUITING NA 50 participants

Outcomes and Cosmesis With Whole Breast Irradiation and Boost

University of Wisconsin, Madison

NCT06295744

RECRUITING NA 40 participants

Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)

University of California, San Francisco

NCT06215469

RECRUITING Phase 2 40 participants

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

University of Illinois at Chicago

NCT04891068

RECRUITING NA 30 participants

Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT06536881

RECRUITING NA 18 participants

SABER Study for Selected Early Stage Breast Cancer

University of Miami

NCT04360330

ACTIVE NOT RECRUITING 100 participants

A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients

MedStar Franklin Square Medical Center

NCT03561454

ACTIVE NOT RECRUITING 94 participants

IORT-Breast at Medical Center Navicent Health

Wake Forest University Health Sciences

NCT04595435

ACTIVE NOT RECRUITING Phase 2 90 participants

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Dana-Farber Cancer Institute

NCT06001762

ACTIVE NOT RECRUITING Phase 1 30 participants

Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA

University of Texas Southwestern Medical Center

NCT02685332

COMPLETED Phase 2 127 participants

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

Dana-Farber Cancer Institute

NCT02698891

COMPLETED Phase 2 100 participants

Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer

Dana-Farber Cancer Institute

NCT00165243

COMPLETED NA 96 participants

POWER-remote Weight Loss Program in Early Stage Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01871116

COMPLETED Phase 1 75 participants

Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer

University of Texas Southwestern Medical Center

NCT01162200

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 9

Named interventions

Most-linked intervention names on Early Stage Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Anastrozole Drug
2 trials
Neulasta Drug
1 trials
Self-directed Behavioral
1 trials
POWER-remote Behavioral
1 trials
Tangential radiation Procedure
1 trials
IORT Device
1 trials
Intraoperative Radiation Therapy Radiation
1 trials
Intraoperative Radiation Therapy (IORT) Radiation
1 trials

US sites by state

Facility locations filed on Early Stage Breast Cancer trials. A trial with sites in several states counts in each.

California 5 trials
Massachusetts 4 trials
New Hampshire 3 trials
Maryland 3 trials
Illinois 3 trials
Florida 3 trials
Connecticut 3 trials
Wisconsin 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Early Stage Breast Cancer page

22 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Early Stage Breast Cancer condition card totals 22 registered trials; most-linked intervention Anastrozole; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.